Free Trial

Janux Therapeutics (JANX) Stock Price, News & Analysis

+1.08 (+2.38%)
(As of 03:16 PM ET)
Today's Range
50-Day Range
52-Week Range
360,159 shs
Average Volume
777,023 shs
Market Capitalization
$2.41 billion
P/E Ratio
Dividend Yield
Price Target

Janux Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
53.4% Upside
$69.50 Price Target
Short Interest
9.55% of Float Sold Short
Dividend Strength
News Sentiment
1.45mentions of Janux Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.34) to ($1.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.35 out of 5 stars

Medical Sector

302nd out of 931 stocks

Pharmaceutical Preparations Industry

137th out of 433 stocks

JANX stock logo

About Janux Therapeutics Stock (NASDAQ:JANX)

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

JANX Stock Price History

JANX Stock News Headlines

Analyst Ratings For Janux Therapeutics
Stocks See Continued Pressure as Bond Yields Climb
Janux Therapeutics Inc Ordinary Shares JANX
Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
See More Headlines
Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$8.08 million
Book Value
$7.46 per share


Free Float
Market Cap
$2.41 billion
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Dr. David Alan Campbell Ph.D. (Age 64)
    President, CEO & Director
    Comp: $1.04M
  • Mr. Charles M. Winter (Age 55)
    Chief Technical Officer
    Comp: $590.4k
  • Mr. Byron Robinson J.D. (Age 59)
    Ph.D., Chief Strategy Officer
    Comp: $723k
  • Mr. Tighe M. Reardon C.F.A. (Age 48)
    CPA, Acting Chief Financial Officer
  • Dr. Tommy Diraimondo Ph.D. (Age 38)
    Chief Scientific Officer
  • Mr. James Pennington
    General Counsel
  • Ms. Brenda Van Vreeswyk
    Head of Human Resources
  • Mr. Andy Hollman Meyer (Age 40)
    Chief Business Officer

JANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Janux Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" JANX shares.
View JANX analyst ratings
or view top-rated stocks.

What is Janux Therapeutics' stock price target for 2024?

7 brokerages have issued 1-year price objectives for Janux Therapeutics' shares. Their JANX share price targets range from $48.00 to $100.00. On average, they expect the company's stock price to reach $69.50 in the next twelve months. This suggests a possible upside of 53.4% from the stock's current price.
View analysts price targets for JANX
or view top-rated stocks among Wall Street analysts.

How have JANX shares performed in 2024?

Janux Therapeutics' stock was trading at $10.73 at the start of the year. Since then, JANX stock has increased by 322.3% and is now trading at $45.31.
View the best growth stocks for 2024 here

When is Janux Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our JANX earnings forecast

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) issued its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The company had revenue of $1.25 million for the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative net margin of 762.92% and a negative trailing twelve-month return on equity of 13.49%.

What ETFs hold Janux Therapeutics' stock?

ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).Fidelity Disruptive Medicine ETF (FMED).

When did Janux Therapeutics IPO?

Janux Therapeutics (JANX) raised $152 million in an initial public offering (IPO) on Friday, June 11th 2021. The company issued 9,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

Who are Janux Therapeutics' major shareholders?

Janux Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.63%), Janus Henderson Group PLC (3.79%), Vanguard Group Inc. (2.62%), Lord Abbett & CO. LLC (1.05%), Altitude Crest Partners Inc. (0.37%) and StemPoint Capital LP (0.23%). Insiders that own company stock include Corp Bregua, Orbimed Advisors Llc, Ra Capital Management, LP and Ventures Xi LP Avalon.
View institutional ownership trends

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:JANX) was last updated on 5/28/2024 by Staff

From Our Partners